Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic

Background In Australia, tixagevimab/cilgavimab 150 mg/150 mg was a government-funded pre-exposure prophylaxis for COVID-19 people with multiple sclerosis (pwMS) and other neuroimmunological conditions (pwNIc) treated with anti-CD20 antibodies or sphingosine-1-phosphate receptor modulators were elig...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Helmut Butzkueven, Wei Zhen Yeh, Mastura Monif, Robb Wesselingh, Louise Rath, Olga Skibina, Cassie Nesbitt, Nabil Seery, Anneke van der Walt, Francesca Bridge, Michael Zhong, Tracie Tan, Angie Roldan, YiChao Foong
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMJ Publishing Group 2024-04-01
Edice:	BMJ Neurology Open
On-line přístup:	https://neurologyopen.bmj.com/content/6/1/e000667.full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!